Definition A clinical trial that asked if adding extracorporeal shock wave (ECW) treatment to intracoronary administration of autologous bone marrow-derived mononuclear cells* (BMCs) would improve homing of BMCs to damaged target tissue.
Conclusion Yes. In patients with post-infarction chronic heart failure, ECW facilitated intracoronary administration of BMCs, resulting in a modest, but statistically significant improvement of LVEF–left ventricular ejection fraction, compared to shock wave treatment alone.
*Which has been shown to improve cardiac functional recovery in patients who had an acute myocardial infarction in a background of end-stage heart failure.
Reference JAMA 2013;309(15):1622-1631